Patent ID: 7056889
Filing Date: 2006-06-06
Classification: A61K

Abstract:
1. A method for modulating the activity of a P2Y 2 or P2Y 1 receptor in a mucosal surface of a mammal comprising administering to the mammal in need thereof a composition comprising a daily effective dose of about 0.001 mg to about 50 mg of a compound that can bind a P2Y 2 or P2Y 1 receptor and a pharmaceutically acceptable excipient, wherein the compound comprises any one of p-nitrobenzyloxycarbonyloxysuccinimide; 1-benzyl-2-2-5-dioxotetrahydro-1H-pyrrol-1-yl-pyrrolidine-1-2-dicarboxylate; 5-(3-methoxycarbonylacryloyl)isophthalic acid dimethyl ester; 6-O-β-glucopyranosyl-β-D-glucose; cyclobutane-1-2-3-4-tetracarboxylic acid dimethyl ester; mono-2-acryloyloxyethyl-succinate; 2-benzyloxycarbonylamino-3-methylbutyric acid, 2-5-dioxo-pyrrolidin-1-yl-ester; tris(trichlorosilylethyl)methylsilane; 2-5-dioxotetrahydro-1H-pyrrol-1-yl-2-benzyloxycarbonylamino-3-phenylpropane 2-chloroethylcarbamic acid, 2-5-dioxo-pyrrolidin-1-yl ester; mono-2-methacryloyloxyethyl-succinate; 3-beta-hydroxy-5-alpha-androstan-17-one-beta-D-glucoside; N-4-5-dimethoxy-2-nitrobenzyloxycarbonyl-L-tryptophan; 2-amino-2-4-chlorobenzoyloxyiminoethyl-pivalate; disuccinimidyl sebacate; 2-2-2-trichloro-1-2-methoxy-phenylamino-ethyl-carbamic-acid-benzyl-ester; 2-acetamido-2-deoxy-6-O-beta-D-galactopyranosyl-D-galactopyranose; 2-benzyloxycarbonylamino-3-hydroxy-propionylaminoacetic acid ethyl ester; 2-benzyloxycarbonylmethylsulfanyl-6-hydroxy-pyrimidine-4-carboxylic-acid-methyl-ester-3-(2-2-2-trichloro-1-isobutyrylamino)ethylthioureidobenzoic acid; ester of 2-diazo-1-naphthol-5-sulphone with 2-3-4-trihydroxybenzophenone; 4-5-dihydroxy-6-hydroxymethyl-2-methoxy-4H-pyran-3-yl-carbamic acid benzyl ester; diethyl-trans-1-2-cyclopropanedicarboxylate; 2-allyloxycarbonylmethylsulfanyl-6-hydroxy-pyrimidine-4-carboxylic acid methyl ester; 1-O-alpha-D-glucopyranosyl-D-fructose; methyl-2-2-4-chlorophenylsulfonylamino-acetylamino-2-phenylacetate; N-(2-hydroxy-4-oxo-4-phenylbut-2-enoyl)-2-methylquinoline-4-carbohydrazide; or DL-Djenkolic-acid, with the proviso that when the compound is 6-O-β-glucopyranosyl-β-D-glucose or DL-Djenkolic-acid, said composition is not administered dermally or transdermally.